Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil monotherapy in benign prostatic hyperplasia: a randomised phase III trial. [PDF]
BJU IntLee SW +20 more
europepmc +1 more source
SRD5A2 and emerging therapies in androgen-driven disorders. [PDF]
Nat Rev UrolWang Z, Gu B, Sharkey C, Ge R, Olumi AF.
europepmc +1 more source
Recurrent Anti-AMPA Receptor Limbic Encephalitis: A Case Report and Literature Review. [PDF]
Front Neurol, 2021 Fang Y, Pan D, Huang H.
europepmc +1 more source
Dutasteride, a 5 alpha reductase inhibitor, could be associated with the exacerbation of inflammation in patients with benign prostatic hyperplasia. [PDF]
Int J UrolInamura S +9 more
europepmc +1 more source
Steroid diversification by multicomponent reactions. [PDF]
Beilstein J Org Chem, 2019 Reguera L +3 more
europepmc +1 more source
Anticancer Activities of Natural and Synthetic Steroids: A Review. [PDF]
ACS OmegaMendoza Lara DF +4 more
europepmc +1 more source
Does insulin resistance predict prostate cancer? Results from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial. [PDF]
CancerZheng R +7 more
europepmc +1 more source
SAR Analysis of Small Molecules Interfering with Energy-Metabolism in Mycobacterium tuberculosis. [PDF]
Pharmaceuticals (Basel), 2020 Appetecchia F +4 more
europepmc +1 more source
Model-based meta-analysis of the time to first acute urinary retention or benign prostatic hyperplasia-related surgery in patients with moderate or severe symptoms. [PDF]
Br J Clin Pharmacol, 2021 D'Agate S +7 more
europepmc +1 more source
More than cholesterol catabolism: regulatory vulnerabilities in Mycobacterium tuberculosis. [PDF]
Curr Opin Chem Biol, 2018 Bonds AC, Sampson NS.
europepmc +1 more source